Aroa Biosurgery was founded in 2008, based on the regenerative properties of ruminant forestomach extracellular matrix technology initially investigated and developed by Dr Brian Ward. The company, which was formerly called Mesynthes, initially contracted scientists from Industrial Research Ltd to get started and then rapidly transitioned to its own internal development team to accelerate commercialisation. Early in 2014, Aroa relocated and expanded into a new purpose built facility in Auckland, New Zealand.
Endoform Dermal Template, our first product for chronic non-healing wounds, was launched in the United States by Hollister Inc. (USA) in 2013 after obtaining U.S. Food & Drug Administration (FDA) clearance and breakthrough reimbursement from the Centre for Medicare and Medicaid Services for an extracellular matrix based product allowing widespread access in all sites of care.
Our first commercial surgical product, a Reinforced Bioscaffold developed in collaboration with Tela Bio Inc. (USA), was cleared by the FDA in December 2014 and clinical studies were initiated in the United States in May 2015 for use in ventral hernia repair and abdominal wall reconstruction.